JP7788376B2 - 最適化されたｇｉｐペプチド類縁体 - Google Patents

最適化されたｇｉｐペプチド類縁体

Info

Publication number
JP7788376B2
JP7788376B2 JP2022532697A JP2022532697A JP7788376B2 JP 7788376 B2 JP7788376 B2 JP 7788376B2 JP 2022532697 A JP2022532697 A JP 2022532697A JP 2022532697 A JP2022532697 A JP 2022532697A JP 7788376 B2 JP7788376 B2 JP 7788376B2
Authority
JP
Japan
Prior art keywords
amino acid
gip
seq
peptide
fatty acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022532697A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023505441A (ja
JP2023505441A5 (enExample
Inventor
ロースンキーレ，メッテ，マリー
スパール‐ウリッチ，アレクサンダー，ホヴァード
リバー，ディッテ
サンニ，サムラ，ジョーク
Original Assignee
アンタグ セラピューティクス エーピーエス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2019/083506 external-priority patent/WO2020115048A1/en
Application filed by アンタグ セラピューティクス エーピーエス filed Critical アンタグ セラピューティクス エーピーエス
Publication of JP2023505441A publication Critical patent/JP2023505441A/ja
Publication of JP2023505441A5 publication Critical patent/JP2023505441A5/ja
Priority to JP2025141835A priority Critical patent/JP2025172864A/ja
Application granted granted Critical
Publication of JP7788376B2 publication Critical patent/JP7788376B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/645—Secretins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2022532697A 2019-12-03 2020-12-03 最適化されたｇｉｐペプチド類縁体 Active JP7788376B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025141835A JP2025172864A (ja) 2019-12-03 2025-08-28 最適化されたｇｉｐペプチド類縁体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/EP2019/083506 WO2020115048A1 (en) 2018-12-03 2019-12-03 Modified gip peptide analogues
EPPCT/EP2019/083506 2019-12-03
EP20179259.5 2020-06-10
EP20179259 2020-06-10
PCT/EP2020/084487 WO2021110845A1 (en) 2019-12-03 2020-12-03 Optimized gip peptide analogues

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025141835A Division JP2025172864A (ja) 2019-12-03 2025-08-28 最適化されたｇｉｐペプチド類縁体

Publications (3)

Publication Number Publication Date
JP2023505441A JP2023505441A (ja) 2023-02-09
JP2023505441A5 JP2023505441A5 (enExample) 2023-12-12
JP7788376B2 true JP7788376B2 (ja) 2025-12-18

Family

ID=71083547

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022532697A Active JP7788376B2 (ja) 2019-12-03 2020-12-03 最適化されたｇｉｐペプチド類縁体
JP2025141835A Pending JP2025172864A (ja) 2019-12-03 2025-08-28 最適化されたｇｉｐペプチド類縁体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025141835A Pending JP2025172864A (ja) 2019-12-03 2025-08-28 最適化されたｇｉｐペプチド類縁体

Country Status (10)

Country Link
US (1) US20250346647A2 (enExample)
EP (1) EP4069719A1 (enExample)
JP (2) JP7788376B2 (enExample)
KR (1) KR20220108064A (enExample)
CN (1) CN114761420B (enExample)
AU (1) AU2020398675A1 (enExample)
CA (1) CA3157387A1 (enExample)
IL (1) IL293249A (enExample)
MX (1) MX2022006737A (enExample)
WO (1) WO2021110845A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3221661A1 (en) * 2021-06-10 2022-12-15 Alexander HOVARD SPARRE-ULRICH Treatment of obesity and obesity-related disorders
WO2023139106A2 (en) * 2022-01-18 2023-07-27 Novo Nordisk A/S Long-acting gipr antagonists
EP4556487A1 (en) * 2022-07-13 2025-05-21 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Glp-1/gip dual agonist, and preparation method therefor and use thereof
TW202529796A (zh) * 2023-11-22 2025-08-01 大陸商杭州中美華東製藥有限公司 Glp-1r/gipr雙標靶激動劑在製備動物藥的用途
WO2025259957A1 (en) * 2024-06-14 2025-12-18 Eli Lilly And Company Compositions and methods for improving insulin sensitivity

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008530130A (ja) 2005-02-11 2008-08-07 アミリン・ファーマシューティカルズ，インコーポレイテッド Ｇｉｐ類似体および選択可能な特性を備えるハイブリッドポリペプチド
JP2010500996A (ja) 2006-08-17 2010-01-14 アミリン・ファーマシューティカルズ，インコーポレイテッド 選択可能な特性を持つｄｐｐ−ｉｖ耐性ｇｉｐハイブリッドポリペプチド
JP2011530508A (ja) 2008-08-07 2011-12-22 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ グルコース依存性インスリン分泌刺激ポリペプチドのアナログ
JP2011530507A (ja) 2008-08-07 2011-12-22 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ グルコース依存性インスリン分泌刺激ポリペプチドアナログ
WO2016034186A1 (en) 2014-09-05 2016-03-10 University Of Copenhagen Gip peptide analogues
JP2022509568A (ja) 2018-12-03 2022-01-20 アンタグ セラピューティクス エーピーエス 修飾されたｇｉｐペプチド類似体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263545B2 (en) * 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
CN101155828A (zh) * 2005-02-11 2008-04-02 安米林药品公司 Gip类似物和具有可选择性质的杂合多肽
WO2010016936A1 (en) * 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Pharmaceutical compositions of analogues of glucose-dependent insulinotropic polypeptide
CN107129538B (zh) * 2010-04-27 2021-07-16 西兰制药公司 Glp-1受体激动剂和胃泌素的肽缀合物及其用途
IN2014MN02304A (enExample) * 2012-05-03 2015-08-07 Zealand Pharma As
KR102743887B1 (ko) * 2017-05-31 2024-12-19 유니버시티 오브 코펜하겐 장기-작용성 gip 펩타이드 유사체
AR113486A1 (es) * 2017-12-21 2020-05-06 Lilly Co Eli Análogos de incretina y sus usos

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008530130A (ja) 2005-02-11 2008-08-07 アミリン・ファーマシューティカルズ，インコーポレイテッド Ｇｉｐ類似体および選択可能な特性を備えるハイブリッドポリペプチド
JP2010500996A (ja) 2006-08-17 2010-01-14 アミリン・ファーマシューティカルズ，インコーポレイテッド 選択可能な特性を持つｄｐｐ−ｉｖ耐性ｇｉｐハイブリッドポリペプチド
JP2011530508A (ja) 2008-08-07 2011-12-22 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ グルコース依存性インスリン分泌刺激ポリペプチドのアナログ
JP2011530507A (ja) 2008-08-07 2011-12-22 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ グルコース依存性インスリン分泌刺激ポリペプチドアナログ
WO2016034186A1 (en) 2014-09-05 2016-03-10 University Of Copenhagen Gip peptide analogues
JP2022509568A (ja) 2018-12-03 2022-01-20 アンタグ セラピューティクス エーピーエス 修飾されたｇｉｐペプチド類似体

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
IRWIN, N et al.，GIP(Lys16PAL) and GIP(LYS37PAL): Novel Long-Acting Acylated Analogues of Glucose-Dependent Insulinotropic Polypeptide with Improved Antidiabetic Potential，Journal of Medicinal Chemistry，2006年，Vol. 49，pp. 1047-1054
PATHAK, V et al.，Antagonism of gastric inhibitory polypeptide (GIP) by palmitoylation of GIP analogues with N- and C-terminal modifications improves obesity and metabolic control in high fat fed mice，Molecular and Cellular Endocrinology，2015年，Vol. 401，pp. 120-129
PATHAK, V et al.，Sequential induction of beta cell rest and stimulation using stable GIP inhibitor and GLP-1 mimetic peptides improves metabolic control in C57BL/KsJ db/db mice，Diabetologia，2015年，Vol. 58，pp. 2144-2153

Also Published As

Publication number Publication date
US20250346647A2 (en) 2025-11-13
MX2022006737A (es) 2022-06-14
EP4069719A1 (en) 2022-10-12
JP2023505441A (ja) 2023-02-09
JP2025172864A (ja) 2025-11-26
IL293249A (en) 2022-07-01
CA3157387A1 (en) 2021-06-10
CN114761420B (zh) 2026-04-28
WO2021110845A1 (en) 2021-06-10
CN114761420A (zh) 2022-07-15
US20230416330A1 (en) 2023-12-28
KR20220108064A (ko) 2022-08-02
AU2020398675A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
JP7605747B2 (ja) 修飾されたｇｉｐペプチド類似体
JP7788376B2 (ja) 最適化されたｇｉｐペプチド類縁体
KR102351313B1 (ko) Gip/glp1 공효능제 화합물
CN110691788B (zh) 长效gip肽类似物
RU2858286C2 (ru) Оптимизированные пептидные аналоги gip
RU2817673C2 (ru) Модифицированные аналоги GIP пептида
EA048422B1 (ru) Соединения-коагонисты gip/glp1
HK1169998A1 (en) Gip receptor-active glucagon compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250407

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250828

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251202

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251208

R150 Certificate of patent or registration of utility model

Ref document number: 7788376

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150